Cardlytics

Cardlytics, Inc. engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded by Scott D. Grimes, Lynne M. Laube, and Hans Theisen on June 26, 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cardlytics reports robust Q4 performance and eyes positive cash flow

Cardlytics delivered a strong performance in Q4 2022, marked by robust financial results and operational improvements.
The company's strategic focus on cost management, product enhancements, and consumer engagement bodes well for future growth.
While facing challenges in a competitive landscape, Cardlytics is poised to capitalize on opportunities through innovation and strategic initiatives.
Guidance for Q1 2023 and the target for positive free cash flow in Q3 2023 reflect a positive outlook for the company's financial health.

Cardlytics (CDLX) surpasses Q1 expectations amidst cautious advertiser sentiment

Cardlytics (CDLX) reported strong Q1 2023 earnings, exceeding expectations with growth in unique consumers activating offers and improved cost discipline.
The company faces challenges from cautious advertisers and client concentration risks, requiring strategic management and diversification efforts.
Opportunities for growth include expanding the partner network, driving user engagement, and innovating in product offerings to maintain competitiveness.

Cardlytics reports mixed Q2 results, eyes partnerships for growth

Cardlytics navigated mixed financial results in Q2 2023, focusing on cost optimizations and strategic initiatives. The company aims for positive annual adjusted EBITDA and operating cash flow in 2024 amidst market variability and economic uncertainty.

Cardlytics reports positive Q3 results, eyes global expansion and new products

Cardlytics delivered positive Q3 results, showcasing growth in revenue, partnerships, and strategic initiatives. Challenges include revenue factors and product adoption, while opportunities exist in new product offerings and global expansion. The company remains optimistic about future prospects and business success.

Cardlytics reports record Q4 earnings, eyes growth through redemptions

Cardlytics achieved a milestone with its first positive annual adjusted EBITDA since 2019 and recorded its largest adjusted EBITDA in Q4. The company is strategically positioned for growth with new partnerships, product launches, and a focus on driving redemptions. Challenges lie in maintaining financial performance and capital structure.

Cardlytics (CDLX) posts robust Q1 results, eyes growth opportunities

Cardlytics (CDLX) reported strong Q1 2024 results with notable billings and revenue growth, positive adjusted EBITDA, and progress in strategic initiatives. While facing challenges in Q2 projections and analyst inquiries, the company remains focused on capitalizing on growth opportunities and market trends.

Cardlytics reports mixed Q2 results, focuses on growth opportunities

Cardlytics shows resilience with positive adjusted EBITDA in 2023 and improved financial stability
Despite missing Q2 guidance, the company is addressing delivery issues and focusing on growth areas
Strong relationships with financial institutions and plans for business evolution under new leadership
Q3 outlook includes challenges but also opportunities for expansion and performance acceleration

Cardlytics faces Q3 revenue decline, eyes growth through strategic investments

Cardlytics navigated Q3 challenges with a focus on enhancing key aspects of its business. The company's strategic priorities include supply, demand, network performance, and investments in growth initiatives like Bridg and Rippl.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardlytics, Inc. engages in the business of operating an advertising platform which includes online, mobile applications, email, and various real-time notifications. It operates under the Cardlytics and Bridg Platforms. The Cardlytics Platform segment focuses on the United States and the United Kingdom, which represents proprietary advertising channels. The Bridg Platform segment is involved in utilizing POS data from merchant data partners, including product-level purchase data to enable marketers to perform analytics and targeted loyalty marketing in a privacy protected manner. The company was founded by Scott David Grimes, Lynne Marie Laube, and Hans Theisen on June 26, 2008 and is headquartered in Atlanta, GA.

NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Cardlytics, Inc. (CDLX) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Opened An Inquiry Into Cardlytics Inc. For Securities Fraud And Stakeholders Are Urged To Join

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc. Is Being Investigated By The Schall Law Firm For Securities Law Violations And Impacted Investors Are Invited To Be A Part

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Investors to Contact the Firm Today!

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Cardlytics Inc. Investors To Join A Securities Fraud Investigation

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Stockholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Cardlytics, Inc. (CDLX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

Did Cardlytics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CDLX

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders With Losses In Cardlytics Inc. Are Encouraged To Participate In Securities Fraud Case With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Stockholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Investors who lost money on Cardlytics, Inc. should contact Levi & Korsinsky about an ongoing investigation - CDLX

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Cardlytics Inc. Invited To Join The Schall Law Firm In Securities Fraud Case

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

Cardlytics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - CDLX

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks' digital channels, today announced that, on August 19, 2024, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 49,900 restricted stock units of Cardlytics to seven newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”).

Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardlytics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - CDLX

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders With Losses In Cardlytics Inc. Encouraged To Participate In Securities Fraud Case With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc. Investors Can Participate In Securities Fraud Case With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX). Investors who purchased Cardlytics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDLX.

CDLX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Cardlytics, Inc. and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Cardlytics Inc. Shareholders Invited To Join Securities Fraud Case With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.

CDLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cardlytics, Inc.

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Cardlytics Stock (CDLX)